192 related articles for article (PubMed ID: 31380598)
1. Quinazoline based 1,3,5-triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: Design, synthesis, docking, and QSAR study.
Pathak P; Naumovich V; Grishina M; Shukla PK; Verma A; Potemkin V
Arch Pharm (Weinheim); 2019 Sep; 352(9):e1900053. PubMed ID: 31380598
[TBL] [Abstract][Full Text] [Related]
2. Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: design, synthesis, docking, in vitro cytotoxicity and in ovo antiangiogenic activity.
Pathak P; Shukla PK; Kumar V; Kumar A; Verma A
Inflammopharmacology; 2018 Dec; 26(6):1441-1453. PubMed ID: 29663100
[TBL] [Abstract][Full Text] [Related]
3. Hybrid Quinazoline 1,3,5-Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study.
Pathak P; Rimac H; Grishina M; Verma A; Potemkin V
ChemMedChem; 2021 Mar; 16(5):822-838. PubMed ID: 33155373
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
[TBL] [Abstract][Full Text] [Related]
6. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Antitumor Activity of Novel Quinazoline Derivatives.
Wang L; Li P; Li B; Wang Y; Li J; Song L
Molecules; 2017 Sep; 22(10):. PubMed ID: 28956845
[TBL] [Abstract][Full Text] [Related]
8. Uses of cyclohexane-1,3-dione for the synthesis of 1,2,4-triazine derivatives as anti-proliferative agents and tyrosine kinases inhibitors.
Megally Abdo NY; Milad Mohareb R; Halim PA
Bioorg Chem; 2020 Apr; 97():103667. PubMed ID: 32087416
[TBL] [Abstract][Full Text] [Related]
9. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of substituted pyrido[3,2-d]-1,2,3-triazines as potential Pim-1 inhibitors.
Fan YB; Li K; Huang M; Cao Y; Li Y; Jin SY; Liu WB; Wen JC; Liu D; Zhao LX
Bioorg Med Chem Lett; 2016 Feb; 26(4):1224-8. PubMed ID: 26804231
[TBL] [Abstract][Full Text] [Related]
13. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
14. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo[2,1-f][1,2,4]triazine derivatives.
Xiang HY; Chen YH; Wang Y; Zhang X; Ding J; Meng LH; Yang CH
Bioorg Med Chem Lett; 2020 Jun; 30(12):127194. PubMed ID: 32317209
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
OuYang Y; Zou W; Peng L; Yang Z; Tang Q; Chen M; Jia S; Zhang H; Lan Z; Zheng P; Zhu W
Eur J Med Chem; 2018 Jun; 154():29-43. PubMed ID: 29775935
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
Dao P; Smith N; Tomkiewicz-Raulet C; Yen-Pon E; Camacho-Artacho M; Lietha D; Herbeuval JP; Coumoul X; Garbay C; Chen H
J Med Chem; 2015 Jan; 58(1):237-51. PubMed ID: 25180654
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of quinazolines as tyrosine kinase inhibitors.
Srivastava SK; Kumar V; Agarwal SK; Mukherjee R; Burman AC
Anticancer Agents Med Chem; 2009 Mar; 9(3):246-75. PubMed ID: 19275520
[TBL] [Abstract][Full Text] [Related]
20. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
